The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Konovalov A.N.
Burdenko Neurosurgical Center
Maryashev S.A.
Burdenko National Medical Scientific Center for Neurosurgery
Pitskhelauri D.I.
Burdenko Neurosurgical Center
Golanov A.V.
Burdenko Neurosurgical Center
Pronin I.N.
Burdenko Neurosurgical Center
Dalechina A.V.
«Business Center of Neurosurgery» JSC
Antipina N.A.
Burdenko Neurosurgical Center
Central neurocytomas: long-term treatment outcomes
Journal: Burdenko's Journal of Neurosurgery. 2021;85(2): 5‑16
Views: 2979
Downloaded: 108
To cite this article:
Konovalov AN, Maryashev SA, Pitskhelauri DI, et al. . Central neurocytomas: long-term treatment outcomes. Burdenko's Journal of Neurosurgery.
2021;85(2):5‑16. (In Russ., In Engl.)
https://doi.org/10.17116/neiro2021850215
Central neurocytoma is a rare benign brain tumor. These tumors may be giant and accompanied by compression of ventricular system and surrounding structures. Modern treatment of brain neurocytoma includes extended resection and restoration of normal CSF circulation. Surgical treatment does not often lead to total resection of these tumors. Redo resection was preferred in patients with tumor progression for a long time. In the last decade, various authors report stereotactic irradiation for continued tumor growth to ensure local growth control. This study was aimed at evaluation of postoperative outcomes in patients with brain neurocytomas, as well as treatment of tumor progression in long-term period.
To analyze recurrence-free survival in patients with brain neurocytomas, risk factors of recurrence-free survival, effectiveness of various treatments for tumor progression and delayed complications.
Long-term postoperative follow-up data of patients with brain neurocytomas are reported in the manuscript. We analyzed recurrence-free survival and risk factors of recurrence-free survival, treatment outcomes in patients with progression of brain neurocytomas, long-term complications and their prevention.
Follow-up included 84 out of 115 patients with brain neurocytoma after surgical treatment in 2008—2017. Follow-up period ranged from 2 to 10 years (mean 6 years) after resection. Most patients had regression of neurological symptoms after surgery. Continued tumor growth within 12—96 months after surgery occurred in 26 (30.19%) out of 84 patients (19 cases after partial resection and 7 cases after total resection according to MRI data). Two-year recurrence-free survival was 94%, 5-year survival — 83%. Risk factors of continued tumor growth were resection quality and Ki-67 index. Redo resection was performed in 7 cases. Eleven patients underwent stereotactic irradiation for tumor progression. Indications for stereotactic irradiation of central neurocytoma are MR data on continued growth of lateral ventricle tumor without signs of ICH and CSF flow impairment. There were no cases of hemorrhage inside the residual tumor and CSF flow impairment in early postoperative period after redo resection. In all cases (n=11), stereotactic irradiation (mean follow-up 2.5 years) ensured satisfactory control of tumor growth with reduction of the neoplasm in 4 cases and no tumor growth in 7 cases.
Resection of central neurocytoma ensures long-term recurrence-free period. The main causes of tumor recurrence are partial resection and high proliferative activity (Ki-67 index over 5%). Redo resection is advisable for tumor progression followed by CSF flow impairment. In case of continued growth of neurocytoma without signs of intracranial hypertension, stereotactic irradiation with various fractionation modes ensures effective and safe control of tumor growth.
Authors:
Konovalov A.N.
Burdenko Neurosurgical Center
Maryashev S.A.
Burdenko National Medical Scientific Center for Neurosurgery
Pitskhelauri D.I.
Burdenko Neurosurgical Center
Golanov A.V.
Burdenko Neurosurgical Center
Pronin I.N.
Burdenko Neurosurgical Center
Dalechina A.V.
«Business Center of Neurosurgery» JSC
Antipina N.A.
Burdenko Neurosurgical Center
Received:
20.10.2020
Accepted:
05.02.2020
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.